Abstract
Background: The understanding of pathogenesis is necessary for the development of effective treatment for COVID-19. Various studies have postulated that there is a complex interplay of mediators of coagulation and inflammation responsible for the pathogenesis of COVID-19. We did this study on coagulation parameters and inflammatory markers and their effect on outcome in patients with COVID-19.
Methods: This was a single centre observational cross-sectional study. Procoagulants [Prothrombin time (PT), activated partial thromboplastin time (APTT), D-dimer, lupus anticoagulant (LA), fibrinogen, factor-VIII (F-VIII)]; anticoagulants [protein-C (PC), protein-S (PS), antithrombin] and inflammatory markers [interleukin-6 (IL-6) and highly sensitive – C-reactive protein (hs-CRP)] were measured at the time of hospitalization and correlated with the severity of the disease.
Results: A total of 230 patients were enrolled, of which 61.3%, 20.0%, and 18.7% had asymptomatic/ mild, moderate, or severe disease, respectively. COVID-19 disease severity was associated with rising trends with coagulation parameters (PT, APTT, D-Dimer; p value 0.01, <0.0001, <0.0001, respectively). Falling trends of anticoagulant (PC, Antithrombin; p value <0.0001, 0.003 respectively) and rising trends of procoagulant (fibrinogen, F-VIII; p value 0.004, <0.0001 respectively) were observed with increasing COVID-19 disease severity. Multivariate logistic regression analysis found that advanced age, high D-Dimer, and high hs-CRP (p value 0.035, 0.018, <0.0001 respectively) were independent predictors of mortality in COVID-19. Procoagulant parameters (D-dimer, APTT, Factor VIII) were positively correlated with anticoagulant parameters (PC and PS) and inflammatory parameters (hs-CRP).
Conclusion: This study revealed increased levels of coagulation and inflammatory parameters, which correlated with the severity of COVID-19. Age, D-dimer, IL-6, hs-CRP, APTT, fibrinogen, and Factor VIII were significantly higher in patients with moderate and severe disease as compared to asymptomatic/mild disease. Advanced age, high D-dimer, and high hs-CRP were significantly associated with poor outcomes.
Keywords: COVID-19, coagulation parameters, pro-coagulation parameters, anti-coagulation parameters, inflammatory markers, tertiary care centre.
Graphical Abstract
[1]
Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; Niu, P.; Zhan, F.; Ma, X.; Wang, D.; Xu, W.; Wu, G.; Gao, G.F.; Tan, W. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med., 2020, 382(8), 727-733.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[2]
Gralinski, L.E.; Bankhead, A., III; Jeng, S.; Menachery, V.D.; Proll, S.; Belisle, S.E.; Matzke, M.; Webb-Robertson, B.J.; Luna, M.L.; Shukla, A.K.; Ferris, M.T.; Bolles, M.; Chang, J.; Aicher, L.; Waters, K.M.; Smith, R.D.; Metz, T.O.; Law, G.L.; Katze, M.G.; McWeeney, S.; Baric, R.S. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. MBio, 2013, 4(4), e00271-e13.
[http://dx.doi.org/10.1128/mBio.00271-13] [PMID: 23919993]
[http://dx.doi.org/10.1128/mBio.00271-13] [PMID: 23919993]
[3]
Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; Zhao, Y.; Li, Y.; Wang, X.; Peng, Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020, 323(11), 1061-1069.
[http://dx.doi.org/10.1001/jama.2020.1585] [PMID: 32031570]
[http://dx.doi.org/10.1001/jama.2020.1585] [PMID: 32031570]
[4]
Antoniak, S.; Mackman, N. Multiple roles of the coagulation protease cascade during virus infection. Blood, 2014, 123(17), 2605-2613.
[http://dx.doi.org/10.1182/blood-2013-09-526277] [PMID: 24632711]
[http://dx.doi.org/10.1182/blood-2013-09-526277] [PMID: 24632711]
[5]
Basler, C.F. Molecular pathogenesis of viral hemorrhagic fever. Semin. Immunopathol., 2017, 39(5), 551-561.
[http://dx.doi.org/10.1007/s00281-017-0637-x] [PMID: 28555386]
[http://dx.doi.org/10.1007/s00281-017-0637-x] [PMID: 28555386]
[6]
Chen, T.; Wu, D.; Chen, H.; Yan, W.; Yang, D.; Chen, G.; Ma, K.; Xu, D.; Yu, H.; Wang, H.; Wang, T.; Guo, W.; Chen, J.; Ding, C.; Zhang, X.; Huang, J.; Han, M.; Li, S.; Luo, X.; Zhao, J.; Ning, Q. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ, 2020, 368, m1091. [published correction appears in BMJ. 2020 Mar 31;368:m1295].
[http://dx.doi.org/10.1136/bmj.m1091] [PMID: 32217556]
[http://dx.doi.org/10.1136/bmj.m1091] [PMID: 32217556]
[7]
Lin, J.; Yan, H.; Chen, H. COVID-19 and coagulation dysfunction in adults: A systematic review and meta-analysis. J. Med. Virol., 2020.
[http://dx.doi.org/10.1002/jmv.26346] [PMID: 32706426]
[http://dx.doi.org/10.1002/jmv.26346] [PMID: 32706426]
[8]
Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Ou, C.Q.; He, J.X.; Liu, L.; Shan, H.; Lei, C.L.; Hui, D.S.C.; Du, B.; Li, L.J.; Zeng, G.; Yuen, K.Y.; Chen, R.C.; Tang, C.L.; Wang, T.; Chen, P.Y.; Xiang, J.; Li, S.Y.; Wang, J.L.; Liang, Z.J.; Peng, Y.X.; Wei, L.; Liu, Y.; Hu, Y.H.; Peng, P.; Wang, J.M.; Liu, J.Y.; Chen, Z.; Li, G.; Zheng, Z.J.; Qiu, S.Q.; Luo, J.; Ye, C.J.; Zhu, S.Y.; Zhong, N.S. China medical treatment expert group for covid-19. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med., 2020, 382(18), 1708-1720.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[9]
Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223), 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[10]
Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y.; Li, H.; Wu, X.; Xu, J.; Tu, S.; Zhang, Y.; Chen, H.; Cao, B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, 395(10229), 1054-1062.
[http://dx.doi.org/10.1016/S0140-6736(20)30566-3] [PMID: 32171076]
[http://dx.doi.org/10.1016/S0140-6736(20)30566-3] [PMID: 32171076]
[11]
Yang, X.; Yang, Q.; Wang, Y.; Wu, Y.; Xu, J.; Yu, Y.; Shang, Y. Thrombocytopenia and its association with mortality in patients with COVID-19. J. Thromb. Haemost., 2020, 18(6), 1469-1472.
[http://dx.doi.org/10.1111/jth.14848] [PMID: 32302435]
[http://dx.doi.org/10.1111/jth.14848] [PMID: 32302435]
[12]
Zhang, Y.; Cao, W.; Jiang, W.; Xiao, M.; Li, Y.; Tang, N.; Liu, Z.; Yan, X.; Zhao, Y.; Li, T.; Zhu, T. Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients. J. Thromb. Thrombolysis, 2020, 50(3), 580-586.
[http://dx.doi.org/10.1007/s11239-020-02182-9] [PMID: 32648093]
[http://dx.doi.org/10.1007/s11239-020-02182-9] [PMID: 32648093]
[13]
Tabatabai, A.; Rabin, J.; Menaker, J.; Madathil, R.; Galvagno, S.; Menne, A.; Chow, J.H.; Grazioli, A.; Herr, D.; Tanaka, K.; Scalea, T.; Mazzeffi, M. Factor VIII and functional protein C activity in critically ill patients with coronavirus disease 2019: A case series. A A Pract., 2020, 14(7), e01236.
[http://dx.doi.org/10.1213/XAA.0000000000001236] [PMID: 32539272]
[http://dx.doi.org/10.1213/XAA.0000000000001236] [PMID: 32539272]
[14]
Panigada, M.; Bottino, N.; Tagliabue, P.; Grasselli, G.; Novembrino, C.; Chantarangkul, V.; Pesenti, A.; Peyvandi, F.; Tripodi, A. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J. Thromb. Haemost., 2020, 18(7), 1738-1742.
[http://dx.doi.org/10.1111/jth.14850] [PMID: 32302438]
[http://dx.doi.org/10.1111/jth.14850] [PMID: 32302438]
[15]
MoHFW|Home. Available from: https://www.mohfw.gov.in/dashboard/index.php Accessed 20th July 2020
[16]
Available from: https://www.who.int/publications/i/item/clinical- management-of-covid-19/Downloads/WHO-2019-nCoV-clinical- 2020.5-eng.pdf Accessed 15th August 2020
[17]
Jayarangaiah, A.; Kariyanna, P.T.; Chen, X.; Jayarangaiah, A.; Kumar, A. COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response. Clin. Appl. Thromb. Hemost., 2020, 26, 1076029620943293.
[http://dx.doi.org/10.1177/1076029620943293] [PMID: 32735131]
[http://dx.doi.org/10.1177/1076029620943293] [PMID: 32735131]
[18]
Tang, N.; Li, D.; Wang, X.; Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost., 2020, 18(4), 844-847.
[http://dx.doi.org/10.1111/jth.14768] [PMID: 32073213]
[http://dx.doi.org/10.1111/jth.14768] [PMID: 32073213]
[19]
Sanyaolu, A.; Okorie, C.; Marinkovic, A.; Patidar, R.; Younis, K.; Desai, P.; Hosein, Z.; Padda, I.; Mangat, J.; Altaf, M. Comorbidity and its impact on patients with COVID-19. SN Compr. Clin. Med., 2020, 1-8.
[http://dx.doi.org/10.1007/s42399-020-00363-4] [PMID: 32838147]
[http://dx.doi.org/10.1007/s42399-020-00363-4] [PMID: 32838147]
[20]
Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; Zhang, Y.; Song, J.; Wang, S.; Chao, Y.; Yang, Z.; Xu, J.; Zhou, X.; Chen, D.; Xiong, W.; Xu, L.; Zhou, F.; Jiang, J.; Bai, C.; Zheng, J.; Song, Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med., 2020, 180(7), 934-943.
[http://dx.doi.org/10.1001/jamainternmed.2020.0994] [PMID: 32167524]
[http://dx.doi.org/10.1001/jamainternmed.2020.0994] [PMID: 32167524]
[21]
Gao, Y.; Li, T.; Han, M.; Li, X.; Wu, D.; Xu, Y.; Zhu, Y.; Liu, Y.; Wang, X.; Wang, L. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J. Med. Virol., 2020, 92(7), 791-796.
[http://dx.doi.org/10.1002/jmv.25770] [PMID: 32181911]
[http://dx.doi.org/10.1002/jmv.25770] [PMID: 32181911]
[22]
Chen, G.; Wu, D.; Guo, W.; Cao, Y.; Huang, D.; Wang, H.; Wang, T.; Zhang, X.; Chen, H.; Yu, H.; Zhang, X.; Zhang, M.; Wu, S.; Song, J.; Chen, T.; Han, M.; Li, S.; Luo, X.; Zhao, J.; Ning, Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest., 2020, 130(5), 2620-2629.
[http://dx.doi.org/10.1172/JCI137244] [PMID: 32217835]
[http://dx.doi.org/10.1172/JCI137244] [PMID: 32217835]
[23]
Liu, J.; Li, S.; Liu, J.; Liang, B.; Wang, X.; Wang, H.; Li, W.; Tong, Q.; Yi, J.; Zhao, L.; Xiong, L.; Guo, C.; Tian, J.; Luo, J.; Yao, J.; Pang, R.; Shen, H.; Peng, C.; Liu, T.; Zhang, Q.; Wu, J.; Xu, L.; Lu, S.; Wang, B.; Weng, Z.; Han, C.; Zhu, H.; Zhou, R.; Zhou, H.; Chen, X.; Ye, P.; Zhu, B.; Wang, L.; Zhou, W.; He, S.; He, Y.; Jie, S.; Wei, P.; Zhang, J.; Lu, Y.; Wang, W.; Zhang, L.; Li, L.; Zhou, F.; Wang, J.; Dittmer, U.; Lu, M.; Hu, Y.; Yang, D.; Zheng, X. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine, 2020, 55, 102763.
[http://dx.doi.org/10.1016/j.ebiom.2020.102763] [PMID: 32361250]
[http://dx.doi.org/10.1016/j.ebiom.2020.102763] [PMID: 32361250]
[24]
He, R.; Lu, Z.; Zhang, L.; Fan, T.; Xiong, R.; Shen, X.; Feng, H.; Meng, H.; Lin, W.; Jiang, W.; Geng, Q. The clinical course and its correlated immune status in COVID-19 pneumonia. J. Clin. Virol., 2020, 127, 104361.
[http://dx.doi.org/10.1016/j.jcv.2020.104361] [PMID: 32344320]
[http://dx.doi.org/10.1016/j.jcv.2020.104361] [PMID: 32344320]
[25]
Chen, Q.; Zheng, Z.; Zhang, C.; Zhang, X.; Wu, H.; Wang, J.; Wang, S.; Zheng, C. Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. Infection, 2020, 48(4), 543-551.
[http://dx.doi.org/10.1007/s15010-020-01432-5] [PMID: 32342479]
[http://dx.doi.org/10.1007/s15010-020-01432-5] [PMID: 32342479]
[26]
Wan, S.; Xiang, Y.; Fang, W.; Zheng, Y.; Li, B.; Hu, Y.; Lang, C.; Huang, D.; Sun, Q.; Xiong, Y.; Huang, X.; Lv, J.; Luo, Y.; Shen, L.; Yang, H.; Huang, G.; Yang, R. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J. Med. Virol., 2020, 92(7), 797-806.
[http://dx.doi.org/10.1002/jmv.25783] [PMID: 32198776]
[http://dx.doi.org/10.1002/jmv.25783] [PMID: 32198776]
[27]
Lippi, G.; Favaloro, E.J. D-dimer is associated with severity of coronavirus disease 2019: A pooled analysis. Thromb. Haemost., 2020, 120(5), 876-878.
[http://dx.doi.org/10.1055/s-0040-1709650] [PMID: 32246450]
[http://dx.doi.org/10.1055/s-0040-1709650] [PMID: 32246450]
[28]
Li, Y.; Zhao, K.; Wei, H.; Chen, W.; Wang, W.; Jia, L.; Liu, Q.; Zhang, J.; Shan, T.; Peng, Z.; Liu, Y.; Yan, X. Dynamic relationship between D-dimer and COVID-19 severity. Br. J. Haematol., 2020, 190(1), e24-e27.
[http://dx.doi.org/10.1111/bjh.16797] [PMID: 32420615]
[http://dx.doi.org/10.1111/bjh.16797] [PMID: 32420615]
[29]
Zhu, Z.; Cai, T.; Fan, L.; Lou, K.; Hua, X.; Huang, Z.; Gao, G. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int. J. Infect. Dis., 2020, 95, 332-339.
[http://dx.doi.org/10.1016/j.ijid.2020.04.041] [PMID: 32334118]
[http://dx.doi.org/10.1016/j.ijid.2020.04.041] [PMID: 32334118]
[30]
Fu, J.; Kong, J.; Wang, W.; Wu, M.; Yao, L.; Wang, Z.; Jin, J.; Wu, D.; Yu, X. The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China. Thromb. Res., 2020, 192, 3-8.
[http://dx.doi.org/10.1016/j.thromres.2020.05.006] [PMID: 32407937]
[http://dx.doi.org/10.1016/j.thromres.2020.05.006] [PMID: 32407937]
[31]
Aggarwal, M.; Dass, J.; Mahapatra, M. Hemostatic Abnormalities in COVID-19: An Update. Indian J. Hematol. Blood Transfus., 2020, 1-11.
[PMID: 32837053]
[PMID: 32837053]
[32]
Kraaijenhagen, R.A.; in’t Anker, P.S.; Koopman, M.M.; Reitsma, P.H.; Prins, M.H.; van den Ende, A.; Büller, H.R. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb. Haemost., 2000, 83(1), 5-9.
[http://dx.doi.org/10.1055/s-0037-1613747] [PMID: 10669145]
[http://dx.doi.org/10.1055/s-0037-1613747] [PMID: 10669145]
[33]
Goshua, G.; Pine, A.B.; Meizlish, M.L.; Chang, C.H.; Zhang, H.; Bahel, P.; Baluha, A.; Bar, N.; Bona, R.D.; Burns, A.J.; Dela Cruz, C.S.; Dumont, A.; Halene, S.; Hwa, J.; Koff, J.; Menninger, H.; Neparidze, N.; Price, C.; Siner, J.M.; Tormey, C.; Rinder, H.M.; Chun, H.J.; Lee, A.I. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol., 2020, 7(8), e575-e582.
[http://dx.doi.org/10.1016/S2352-3026(20)30216-7] [PMID: 32619411]
[http://dx.doi.org/10.1016/S2352-3026(20)30216-7] [PMID: 32619411]
[34]
Bowles, L.; Platton, S.; Yartey, N.; Dave, M.; Lee, K.; Hart, D.P.; MacDonald, V.; Green, L.; Sivapalaratnam, S.; Pasi, K.J.; MacCallum, P. Lupus anticoagulant and abnormal coagulation tests in patients with covid-19. N. Engl. J. Med., 2020, 383(3), 288-290.
[http://dx.doi.org/10.1056/NEJMc2013656] [PMID: 32369280]
[http://dx.doi.org/10.1056/NEJMc2013656] [PMID: 32369280]
[35]
Devreese, K.M.J.; Linskens, E.A.; Benoit, D.; Peperstraete, H. Antiphospholipid antibodies in patients with COVID-19: A relevant observation? J. Thromb. Haemost., 2020, 18(9), 2191-2201.
[http://dx.doi.org/10.1111/jth.14994] [PMID: 32619328]
[http://dx.doi.org/10.1111/jth.14994] [PMID: 32619328]
[36]
Harzallah, I.; Debliquis, A.; Drénou, B. Lupus anticoagulant is frequent in patients with Covid-19. J. Thromb. Haemost., 2020, 18(8), 2064-2065.
[http://dx.doi.org/10.1111/jth.14867] [PMID: 32324958]
[http://dx.doi.org/10.1111/jth.14867] [PMID: 32324958]
[37]
Helms, J.; Tacquard, C.; Severac, F.; Leonard-Lorant, I.; Ohana, M.; Delabranche, X.; Merdji, H.; Clere-Jehl, R.; Schenck, M.; Fagot Gandet, F.; Fafi-Kremer, S.; Castelain, V.; Schneider, F.; Grunebaum, L.; Anglés-Cano, E.; Sattler, L.; Mertes, P.M.; Meziani, F. CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med., 2020, 46(6), 1089-1098.
[http://dx.doi.org/10.1007/s00134-020-06062-x] [PMID: 32367170]
[http://dx.doi.org/10.1007/s00134-020-06062-x] [PMID: 32367170]
[38]
Taylor, F.B., Jr; Toh, C.H.; Hoots, W.K.; Wada, H.; Levi, M. Scientific subcommittee on disseminated intravascular coagulation (DIC) of the international society on thrombosis and haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost., 2001, 86(5), 1327-1330.
[http://dx.doi.org/10.1055/s-0037-1616068] [PMID: 11816725]
[http://dx.doi.org/10.1055/s-0037-1616068] [PMID: 11816725]
[39]
Vabret, N.; Britton, G.J.; Gruber, C.; Hegde, S.; Kim, J.; Kuksin, M.; Levantovsky, R.; Malle, L.; Moreira, A.; Park, M.D.; Pia, L.; Risson, E.; Saffern, M.; Salomé, B.; Esai Selvan, M.; Spindler, M.P.; Tan, J.; van der Heide, V.; Gregory, J.K.; Alexandropoulos, K.; Bhardwaj, N.; Brown, B.D.; Greenbaum, B.; Gümüş, Z.H.; Homann, D.; Horowitz, A.; Kamphorst, A.O.; Curotto de Lafaille, M.A.; Mehandru, S.; Merad, M.; Samstein, R.M. Sinai immunology review project. Immunology of COVID-19: Current state of the science. Immunity, 2020, 52(6), 910-941.
[http://dx.doi.org/10.1016/j.immuni.2020.05.002] [PMID: 32505227]
[http://dx.doi.org/10.1016/j.immuni.2020.05.002] [PMID: 32505227]
[40]
Coomes, E.A.; Haghbayan, H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev. Med. Virol., 2020, 30(6), 1-9.
[http://dx.doi.org/10.1002/rmv.2141] [PMID: 32845568]
[http://dx.doi.org/10.1002/rmv.2141] [PMID: 32845568]
[41]
Ulhaq, Z.S.; Soraya, G.V. Interleukin-6 as a potential biomarker of COVID-19 progression. Med. Mal. Infect., 2020, 50(4), 382-383.
[http://dx.doi.org/10.1016/j.medmal.2020.04.002] [PMID: 32259560]
[http://dx.doi.org/10.1016/j.medmal.2020.04.002] [PMID: 32259560]
[42]
Pepys, M.B.; Hirschfield, G.M. C-reactive protein: a critical update. J. Clin. Invest., 2003, 111(12), 1805-1812. [published correction appears in J Clin Invest. 2003 Jul;112(2):299].
[http://dx.doi.org/10.1172/JCI200318921] [PMID: 12813013]
[http://dx.doi.org/10.1172/JCI200318921] [PMID: 12813013]
[43]
Li, Q.; Ding, X.; Xia, G.; Chen, H.G.; Chen, F.; Geng, Z.; Xu, L.; Lei, S.; Pan, A.; Wang, L.; Wang, Z. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study. EClinicalMedicine, 2020, 23, 100375.
[http://dx.doi.org/10.1016/j.eclinm.2020.100375] [PMID: 32368728]
[http://dx.doi.org/10.1016/j.eclinm.2020.100375] [PMID: 32368728]
[44]
Chen, W.; Zheng, K.I.; Liu, S.; Yan, Z.; Xu, C.; Qiao, Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann. Clin. Microbiol. Antimicrob., 2020, 19(1), 18.
[http://dx.doi.org/10.1186/s12941-020-00362-2] [PMID: 32414383]
[http://dx.doi.org/10.1186/s12941-020-00362-2] [PMID: 32414383]
[45]
Liu, F.; Li, L.; Xu, M.; Wu, J.; Luo, D.; Zhu, Y.; Li, B.; Song, X.; Zhou, X. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J. Clin. Virol., 2020, 127, 104370.
[http://dx.doi.org/10.1016/j.jcv.2020.104370] [PMID: 32344321]
[http://dx.doi.org/10.1016/j.jcv.2020.104370] [PMID: 32344321]
[46]
Herold, T.; Jurinovic, V.; Arnreich, C.; Lipworth, B.J.; Hellmuth, J.C.; von Bergwelt-Baildon, M.; Klein, M.; Weinberger, T. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J. Allergy Clin. Immunol., 2020, 146(1), 128-136.e4.
[http://dx.doi.org/10.1016/j.jaci.2020.05.008] [PMID: 32425269]
[http://dx.doi.org/10.1016/j.jaci.2020.05.008] [PMID: 32425269]
[47]
Ji, H.L.; Zhao, R.; Matalon, S.; Matthay, M.A. Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility. Physiol. Rev., 2020, 100(3), 1065-1075.
[http://dx.doi.org/10.1152/physrev.00013.2020] [PMID: 32216698]
[http://dx.doi.org/10.1152/physrev.00013.2020] [PMID: 32216698]
[48]
Giannis, D.; Ziogas, I.A.; Gianni, P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J. Clin. Virol., 2020, 127, 104362.
[http://dx.doi.org/10.1016/j.jcv.2020.104362] [PMID: 32305883]
[http://dx.doi.org/10.1016/j.jcv.2020.104362] [PMID: 32305883]
[49]
Zuo, Y.; Warnock, M.; Harbaugh, A. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. medRxiv, 2020, 2020.08.29.20184358.
[http://dx.doi.org/10.1101/2020.08.29.20184358]
[http://dx.doi.org/10.1101/2020.08.29.20184358]
Article Metrics
12
2
1